ArticleChina CDC weekly2026
Drug Resistance and Risk Factors of Bacteriologically Confirmed Tuberculosis Cases in 10 Sites - Hunan Province, China, 2018-2025.
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Tuberculosis (TB) is a deadly global infectious disease, and China has a high burden of rifampicin-resistant (RR) and multidrug-resistant (MDR) TB, according to the World Health Organization. Prior treatment, Regional disparities, demographics (age/sex), and comorbidities (e.g., diabetes) are associated with an elevated risk of drug-resistant TB. What is added by this report?: We analyzed 25,978 bacteriologically confirmed pulmonary TB (PTB) cases in 10 sites in Hunan Province and found lower first-line drug resistance rates than national/provincial estimates (2018-2025). Retreatment, age 25-44 years, diabetes, and Lengshuitan residence were independent predictors of resistance. Resistance declined during the pandemic, rebounded slightly thereafter, and displayed a 4.0% annual decrease (statistically significant). There was notable inter-county heterogeneity (intraclass correlation coefficient=0.11). Hunan shifted to molecular testing (82.79% of susceptibility tests in 2021-2025). What are the implications for public health practice?: Surveillance should be intensified for groups at high risk of drug-resistant TB, including retreatment patients, those aged 25-44 years, patients with diabetes and TB, and Lengshuitan residents. A scale-up of molecular diagnostic technologies and increased testing panels to cover isoniazid resistance for accurate resistance assessment should be included. Post-pandemic TB control interventions should continue to optimize the quality of routine surveillance data, and in-depth research on non-laboratory factors that lead to regional disparities in drug resistance rates should be performed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.